Tissue Regenix Group PLC Edison research outlook on Tissue Regenix (TRX)
July 28 2016 - 5:58AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
28 July 2016
London, UK, 28 July 2016
Edison issues research outlook on Tissue Regenix (TRX)
Tissue Regenix's (TRX) investment story is built on dCELL, a
versatile regenerative medical technology, and its potential across
the subsectors: wound care, orthopaedics and cardiac implants.
Orthopaedics holds significant promise as the family of dCELL
OrthoPure grafts is targeted at high-growth global markets where
there are few effective alternatives. We have updated our
sum-of-the-parts valuation model to GBP338m, a slight reduction due
to revised product timeline launches, costs and revenue
forecasts.
We have revisited a number of our key valuation assumptions to
reflect the clarity on launch timeframes, associated costs and
updated revenue guidance. Our DCF valuation has reduced to GBP338m
(vs GBP380m) or 44.4p (vs 50p) per share. According to our model,
the current price gives a free option on wound care, the most
commercially advanced division, and does not reflect the full
pipeline potential, which could ultimately be an acquisition target
as a whole or by division.
Click here to view the full report
All reports published by Edison are available to download free
of charge from its website: www.edisoninvestmentresearch.com
About Edison: Edison is an international equity research firm
with a team of over 110 analysts, investment and roadshow
professionals and works with both large and smaller capitalised
companies, blue chip institutional investors, wealth managers,
private equity and corporate finance houses to support their
capital markets activity. Edison provides services to more than 420
retained corporate and investor clients from offices in London, New
York, Frankfurt, Sydney and Wellington. Edison is authorised and
regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
Contact details: Learn more at www.edisongroup.com and connect
with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research
--------- ----------------------------------------------------
Twitter www.twitter.com/Edison_Inv_Res
--------- ----------------------------------------------------
YouTube www.youtube.com/edisonitv
--------- ----------------------------------------------------
Google+ https://plus.google.com/105425025202328783163/posts
--------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGZNLRVGVZG
(END) Dow Jones Newswires
July 28, 2016 05:58 ET (09:58 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024